Department of Vascular Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.
Br J Surg. 2019 Apr;106(5):523-533. doi: 10.1002/bjs.11123. Epub 2019 Mar 18.
Endovascular aneurysm repair (EVAR) has become the preferred strategy for elective repair of abdominal aortic aneurysm (AAA) for many patients. However, the superiority of the endovascular procedure has recently been challenged by reports of impaired long-term survival in patients who underwent EVAR. A systematic review of long-term survival following AAA repair was therefore undertaken.
A systematic review was performed according to PRISMA guidelines. Articles reporting short- and/or long-term mortality of EVAR and open surgical repair (OSR) of AAA were identified. Pooled overall survival estimates (hazard ratios (HRs) with corresponding 95 per cent c.i. for EVAR versus OSR) were calculated using a random-effects model. Possible confounding owing to age differences between patients receiving EVAR or OSR was addressed by estimating relative survival.
Some 53 studies were identified. The 30-day mortality rate was lower for EVAR compared with OSR: 1·16 (95 per cent c.i. 0·92 to 1·39) versus 3·27 (2·71 to 3·83) per cent. Long-term survival rates were similar for EVAR versus OSR (HRs 1·01, 1·00 and 0·98 for 3, 5 and 10 years respectively; P = 0·721, P = 0·912 and P = 0·777). Correction of age inequality by means of relative survival analysis showed equal long-term survival: 0·94, 0·91 and 0·76 at 3, 5 and 10 years for EVAR, and 0·96, 0·91 and 0·76 respectively for OSR.
Long-term overall survival rates were similar for EVAR and OSR. Available data do not allow extension beyond the 10-year survival window or analysis of specific subgroups.
血管内动脉瘤修复术(EVAR)已成为许多患者择期修复腹主动脉瘤(AAA)的首选策略。然而,最近有报道称 EVAR 患者的长期生存率受损,这对血管内手术的优越性提出了挑战。因此,对 AAA 修复后的长期生存率进行了系统评价。
根据 PRISMA 指南进行了系统评价。确定了报告 EVAR 和开放手术修复(OSR)AAA 的短期和/或长期死亡率的文章。使用随机效应模型计算了 EVAR 与 OSR 的总体生存估计(风险比(HR)和相应的 95%置信区间)。通过估计相对生存率来解决 EVAR 或 OSR 患者年龄差异可能导致的混杂。
确定了 53 项研究。EVAR 的 30 天死亡率低于 OSR:1.16(95%置信区间 0.92 至 1.39)与 3.27(2.71 至 3.83)。EVAR 与 OSR 的长期生存率相似(3、5 和 10 年的 HRs 分别为 1.01、1.00 和 0.98;P=0.721、P=0.912 和 P=0.777)。通过相对生存率分析校正年龄不平等后,显示出相同的长期生存率:EVAR 为 3、5 和 10 年时分别为 0.94、0.91 和 0.76,OSR 分别为 0.96、0.91 和 0.76。
EVAR 和 OSR 的长期总体生存率相似。现有数据无法扩展到 10 年生存率窗口之外,也无法分析特定亚组。